“Vaccine Slows Progress of Type 1 Diabetes”

Return to Vaccination News Home Page

Subscribe to the Vaccination NewsLetter

View past & current Scandals (columns by Sandy Mintz)

Immunization Newsbriefs (c) Copyright Information Inc., Bethesda, MD. Brought to you by the National Network for Immunization Information (NNii). Visit NNii's new website at http://www.immunizationinfo.org.

A University of California-Los Angeles study finds that a vaccine candidate could cease the progression of type 1 diabetes in patients who already have the disease. The product specifically boosts a person’s ability to make insulin. A diagnostic test was used to find individuals whose diabetes was likely caused by antibodies to the GAD protein in the pancreas’ insulin-producing cells, the most likely candidates for the vaccine. Diamyd Medical, which has licensed the vaccine research, believes the vaccine’s first use will be to help patients not become dependent on injections of insulin.

Return to Vaccination News Home Page

DISCLAIMER: All information, data, and material contained, presented, or provided here is for general information purposes only and is not to be construed as reflecting the knowledge or opinions of the publisher, and is not to be construed or intended as providing medical or legal advice. The decision whether or not to vaccinate is an important and complex issue and should be made by you, and you alone, in consultation with your health care provider.